Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
Q4 2017
|
VBLT |
|
Phase 3 Results |
Oncology |
Fast Track, Orphan Drug |
|
Q4 2017
|
ESPR |
|
Phase 3 Results |
Other |
None |
|
Q4 2017
|
VICL |
|
Phase 3 Results |
Other |
Orphan Drug |
|
Q4 2017
|
ARNA |
|
Phase 2 Results |
Other |
None |
|
Q4 2017
|
MRUS |
|
Phase 1/2 Results |
Oncology |
None |
|
Q4 2016
|
GWPH |
|
NDA Submission |
Neurology |
Fast Track, Orphan Drug |
|
Q4 2016
|
ITEK |
|
Phase 3 Results |
Opthamology |
None |
|
Q4 2016
|
GTXI |
|
Phase 2 Results |
Oncology |
None |
|
Q4 2016
|
HTBX |
|
Phase 2 Results |
Oncology |
Fast Track |
|
Q4 2016
|
HTBX |
|
Phase 1b Results |
Autoimmune |
None |
|